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Abstract
Background:  Treatment of mouse F9 embryonal carcinoma cells with all-trans retinoic acid (T-
RA) induces differentiation into primitive endodermal type cells. Differentiation requires the action
o f  t h e  r e c e p t o r s  f o r  a l l  t r a n s ,  a n d  9 c i s - r e t i n o i c  a c i d  ( R A R  a n d  R X R ,  r e s p e c t i v e l y )  a n d  i s
accompanied by growth inhibition, changes in cell morphology, increased apoptosis, proteolytic
degradation of the RARγ 2 receptor, and induction of target genes.
Results:  We show that the RNA polymerase II transcription factor TFIID subunits TBP and
TAFII135 are selectively depleted in extracts from differentiated F9 cells. In contrast, TBP and
TAFII135 are readily detected in extracts from differentiated F9 cells treated with proteasome
inhibitors showing that their disappearance is due to targeted proteolysis. This regulatory pathway
is not limited to F9 cells as it is also seen when C2C12 myoblasts differentiate into myotubes.
Targe ti ng of T BP and T AF II135 for proteolysis in F9 cells takes place coordinately with that
previously reported for the RARγ 2 receptor and is delayed or does not take place in RAR mutant
F9 cells where differentiation is known to be impaired or abolished. Moreover, ectopic expression
of  TAFII135  delays  proteolysis  of  the  RARγ 2  receptor  and  impairs  primitive  endoderm
differentiation at an early stage as evidenced by cell morphology, induction of marker genes and
apoptotic response. In addition, enhanced TAFII135 expression induces a novel differentiation
pathway characterised by the appearance of cells with an atypical elongated morphology which are
cAMP resistant.
Conclusions:   These  observations  indicate  that  appropriately  timed  proteolysis  of  TBP  and
TAFII135 is required for normal F9 cell differentiation. Hence,  in addition to transactivators,
targeted proteolysis of basal transcription factors also plays an important role in gene regulation in
response to physiological stimuli.
Background
RNA polymerase II (pol II) transcription factor TFIID
comprises the TATA-binding protein (TBP) and a set of
TBP-associated factors (TAFIIs) [123]. At least 12 TAFIIs
have been identified in TFIID and cloning of their cDNAs
has shown an evolutionary conservation of TAFIIs from
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yeast to mammals [4567]. TAFIIs are not only compo-
nents of the TFIID complex, but a subset of TAFIIs are
also found in the SAGA, PCAF, TFTC/STAGA complexes
which lack TBP [89101112].
TAFII function in living cells has been studied in yeast
where the use of temperature sensitive (TS) mutants has
shown that many TAFIIs are required for transcription of
the majority of yeast genes [1314151617]. In contrast, TS
lesions in TAFII145, TAFII150, and TAFII90 have a less
dramatic effect affecting the expression of only a specific
subset of genes mainly involved in the cell cycle [1819]
(for reviews see [3, 20].
In mammalian cells, a TS mutation in TAFII250 shows
that one of the functions of this protein is cell cycle regu-
lation [21222324]. Genetic experiments indicate that
TAFII30 is required for the viability of mouse F9 embry-
onal carcinoma cells as well as for their differentiation
into parietal endoderm [25]. In the absence of TAFII30,
undifferentiated F9 cells die through apoptosis, but
TAFII30 is not required for survival of retinoic acid dif-
ferentiated F9 cells.
Several studies have also focused on TAFII135. TAFII135
comprises 1083 amino acids and contains multiple func-
tional domains. At least four glutamine-rich domains
have been described. Sp1 and CREB interact with dis-
tinct glutamine-rich domains of TAFII135 and TAFII135
acts as a coactivator in vitro for these activators. In
transfected cells, subdomains of TAFII135 can act as
dominant negative repressors of CREB activity
[262728]. It has further been suggested that some neuro-
degenerative diseases may result from sequestration of
TAFII135 by expanded polyglutamine domains and con-
sequent interference with CREB activity [29]. TAFII135
also contains two conserved regions, CR-I and CR-II,
which are shared with the Drosophila homologue
dTAFII110 and mammalian TAFII105 [27, 30] The CR-II
region is also shared with the yeast homologue yTAFII48
[31, 32] and contains a histone fold domain required for
heterodimerisation with hTAFII20/yTAFII68 [33, 34].
The CR-II domain plays an essential role in the ability of
TAFII135 to potentiate ligand-dependent transactivation
by the the receptor for all-trans retinoic acid (RAR) in
transfected mammalian cells [5, 33]. Aside from these
studies, little is known concerning the role of TAFII135 in
more physiological situations.
An increasing body of evidence indicates that targeted
26S proteasome-mediated proteolysis of transcription
factors is an integral part of the transactivation process.
There is a very tight relationship between the potency of
activation domains and their stability [35363738]. Acti-
vation domains and sequences required for degradation
overlap and mutations in the VP16 activation domain
which impair its function result in enhanced protein sta-
bility [35]. Similarly, ligand-dependent targeted proteol-
ysis of several nuclear receptors has been observed
[39404142]. In the estrogen receptor, the RARα , and the
RXRα , deletion of the α -helix H12 of the ligand binding
domain which is essential for ligand-dependent activa-
tion stabilises these proteins showing that proteolysis
and transactivation are intimately linked [424344]. In
the case of nuclear receptors, their targeted proteolysis
in the presence of ligand may be a mechanism for atten-
uating the physiological response to the ligand. It has
also been suggested that targeted proteolysis is a means
of regulating other physiological responses, such as sign-
aling through STAT factors [45] and heat shock [46].
Although targeted proteolysis of transcriptional activa-
tors has been investigated, it is not known whether com-
ponents of the basal transcription apparatus are subject
to this type of regulation in response to physiological
stimuli. We show here that TBP and TAFII135 are selec-
tively depleted in extracts from T-RA differentiated F9
cells and from differentiated C2C12 cells. This depletion
is due to the selective targeting of TBP and TAFII135 for
proteolytic degradation since depletion is blocked when
cells are treated with proteasome inhibitors. During F9
cell differentiation, degradation of TBP and TAFII135 is
concomitant with that of the RARγ 2, a critical activator
in primitive endoderm differentiation. These results re-
veal a novel pathway controlling the intracellular levels
of these two TFIID components and show that in F9 cells
RA not only induces targeted proteolysis of the RARγ 2,
but also of the basal transcription factors which mediate
transcriptional activation. We further show that stable
ectopic expression of TAFII135 in F9 cells delays the tar-
geted degradation of endogenous TAFII135, TBP, and the
RARγ 2 in response to T-RA. The cells have an enhanced
growth rate and their differentiation into primitive endo-
derm is impaired at an early stage, but they readily dif-
ferentiate into parietal endoderm. Treatment of these
cells with T-RA also induces the appearance of a popula-
tion of cells with an atypical elongated morphology, dis-
tinct from that of the primitive endodermal cells, which
have not been previously documented with wild type F9
cells, and which are resistant to differentiation with
bt2cAMP.
Results
TBP and TAFII135 are selectively depleted in extracts from 
T-RA differentiated F9 cells
F9 cells are a well characterised model for cellular differ-
entiation. In the presence of T-RA, F9 cells differentiate
into primitive or visceral endoderm, and into parietal en-
doderm in the presence of T-RA and bt2cAMP [4748].
Differentiation is accompanied by growth inhibition,BMC Molecular Biology (2001) 2:4 http://www.biomedcentral.com/1471-2199/2/4
characteristic changes in cell morphology, targeted deg-
radation of RARγ 2, induction of marker genes, and in-
creased apoptosis.
To determine whether components of basal transcrip-
tion factor TFIID were subject to regulation during F9
cell differentiation, immunoblotting with monoclonal
antibodies against TBP and a number of TAFIIs, was
used to monitor the levels of the respective proteins in
differentiated cell extracts (see Materials and Methods).
No significant changes in the levels of TAFII100,
TAFII55, TAFII20, TAFII30, and TAFII18, or the largest
subunit of RNA polymerase II were observed between 3
and 10 days of T-RA treatment (Fig. 1A, lanes 1-6 and
data not shown). In striking contrast, TAFII135 and TBP
were strongly and selectively depleted in extracts made
from cells differentiated with T-RA for more than 3 days
(Fig. 1A lanes 1-2) and remained at low levels up until at
least day 10 (lanes 2-5). No such changes were observed
in vehicle treated control cultures (Fig. 1A, lanes 7-12). In
these experiments, TAFII135 and TBP were detected us-
ing two different monoclonal antibodies directed against
distinct epitopes (see Materials and methods). The rele-
vant extracts from T-RA treated cells were also analysed
by staining with Coomassie Brilliant Blue showing that
there was no overall change in the protein profile (Fig.
1B). Therefore, there is a selective depletion of these two
TFIID components in extracts from differentiating cells.
To evaluate the levels of TBP and TAFII135 in extracts
from primitive endodermal cells we performed titration
experiments using serial dilutions of undifferentiated F9
cell extract. Upon prolonged exposure, TAFII135 could
still be detected in a 20-fold dilution of the F9 cell ex-
tract, whereas it was virtually undetectable in extracts
from day 7 differentiated cells (Fig. 1C, lanes 1-5 com-
pared with lane 6). Similarly, TBP was readily detected in
the 20-fold dilution of F9 cell extract, while the levels de-
tected in the differentiated cell extracts were significant-
ly lower (compare lanes 5 and 6).
The above experiments were performed with total cell
extracts made in the presence of 0.5 M KCl. We also
asked whether the depletion of TBP and TAFII135 would
be observed in nuclear extracts from differentiated F9
cells where the nuclei were extracted with 1.0 M KCl to
ensure efficient protein extraction. As observed in total
cell extracts, TAFII135 and TBP were selectively depleted
in nuclear extracts from differentiated cells (Fig. 1D).
TBP and TAFII135 were strongly and selectively depleted
in extracts from visceral endoderm differentiated F9
cells analogous to what was observed in primitive endo-
dermal cells (data not shown). When F9 cells were treat-
ed with T-RA and bt2cAMP to induce parietal endoderm
differentiation, a selective depletion of TBP and
TAFII135 also took place between day 3 and day 5 (Fig. 1E
lanes 1, 2 and 6), however, TBP, but not TAFII135, reap-
peared in parietal endodermal cell extracts around day 9
(lanes 4-5). Together the above results indicate that
there is a specific regulation of TBP and TAFII135 during
F9 cell differentiation.
Depletion of TBP and TAFII135 is not observed in F9 cells 
which are refractory to T-RA.
To determine whether the depletion of TBP and
TAFII135 was intimately linked to the differentiation
process, we examined the regulation of these proteins in
mutant F9 cells with altered differentiation properties.
F9 cells in which the retinoid X receptor α  gene has been
disrupted by homologous recombination (RXRα -/- cells)
are impaired in their response to T-RA [49]. When these
cells are treated with T-RA, the depletion of TBP and
TAFII135 observed in the cell extracts is delayed by al-
most 4 days and takes place only between days 7 and 9
rather than between days 3 and 5 in wild-type cells (Fig.
2A), while no such depletion is seen in extracts from ve-
hicle treated cells (Fig. 2B). In contrast, no significant
change in TBP and TAFII135 is seen in extracts from T-
RA treated RXRα -/-RARγ -/- cells, in which the RARγ
gene has also been disrupted [50, 51] and which are
known to be refractory to T-RA induced differentiation
(Fig. 2C). Thus, the selective depletion of TBP and
TAFII135 requires that the F9 cells respond, at least par-
tially, to T-RA, but does not require full differentiation to
take place.
Depletion of TBP and TAFII135 is due to targeted proteo-
lytic degradation
The depletion of TBP and TAFII135 in extracts from day
3-10 T-RA treated cells could result from transcriptional
or post-transcriptional events. Semi-quantitative re-
verse-transcription PCR (RT-PCR) experiments using
exon-specific oligonucleotide primers showed that there
were no significant changes in the TAFII135 or TBP
mRNA levels during differentiation (data not shown).
This suggests that disappearance of TBP and TAFII135 in
extracts from differentiated cells does not occur at the
transcriptional level, but rather results from a post-tran-
scriptional event.
The peptide aldehyde proteasome inhibitors MG132 and
ALLN have previously been used to investigate the post-
transcriptional regulation of proteins during physiologi-
cal processes [52, 53]. To determine whether the deple-
tion of TAFII135 and TBP observed in the extracts from
late T-RA treated F9 cells was due to their selective pro-
teolysis, we treated T-RA differentiated cells with these
inhibitors on days 3, 4, 5, 6, and 7. After an overnight ex-BMC Molecular Biology (2001) 2:4 http://www.biomedcentral.com/1471-2199/2/4
Figure 1
A. Depletion of TBP and TAFII135 in extracts from differentiated F9 cells. Replica plates of cells were treated with T-RA (or
vehicle, right panel) at day 0 and extracts were subsequently prepared form one 10 cm plate at the day indicated above each
lane. 10 µ g of each cell extract were then subjected to SDS-PAGE transferred to nitrocellulose membranes and the presence
of TBP, and TAFIIs was detected using the described antibodies. The locations of the detected proteins are indicated to the left.
B. The extracts from cells differentiated for 0-9 days used in panel A were subjected to SDS-PAGE and stained with Coomasie
Brilliant Blue. C. Western blot with anti-TBP and TAFII135 antibodies performed on serial dilutions of an extract from undif-
ferentiated F9 cells were compared with an undiluted extract from 7 day differentiated cells. Lanes 1-5 contain 20, 10, 4, 2, and
1 µ g of undifferentiated cell extract and lane 6, 20 µ g of differentiated cell extract. D. Immunoblotting shows that TAFII135 and
TBP are selectively depleted in F9 cell nuclear extracts. E. Extracts were prepared from F9 cells differentiated by the addition
of T-RA and bt2cAMP for the number of days indicated above each lane.
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posure, extracts were prepared (day 4, 5, 6, 7 and 8 ex-
tracts in Figs. 3A and 3B). In the absence of MG132 or
ALLN, TBP and TAFII135 disappeared in the differenti-
ated cell extracts (middle panel Figs. 3A and 3B lanes 6-
10). In contrast, in the presence of the inhibitors both
proteins were readily detected even at late times where
they are normally not observed (lanes 1-5). The levels
were nevertheless lower than those detected in undiffer-
entiated cell extracts. The level of TAFII55, which re-
mains constant during differentiation, is only mildly
increased by the addition of MG132 or ALLN (Figs. 3A
and 3B lower panel, lanes 1-5 and 6-10). The addition of
MG132 or ALLN to non-differentiated cells also resulted
in only a small increase in TBP and TAFII135 levels (Figs.
3A and 3B, top panel compare lanes 1-5 and 6-10). The
above results indicate that when proteolysis is inhibited
the depletion of TBP and TAFII135 is no longer observed
showing that it is due to T-RA-induced proteolytic degra-
dation.
We also prepared extracts from differentiated cells
where MG132 was added only at the time of extract prep-
aration. Extracts made in this way are a measure of the
intracellular level of these proteins since synthesis and
degradation are both stopped at the same time. Compar-
ison of the TBP and TAFII135 levels in extracts from day
7 differentiated cells prepared in the presence of MG132
showed that they were indeed significantly reduced com-
pared to undifferentiated cells or day 3 differentiated
cells (approximately 3 fold, Fig. 3C, lanes 1, 4 and 5, sim-
ilar results were obtained in the presence of ALLN data
not shown). Nevertheless, these proteins do not disap-
pear completely as they do in the absence of MG132
(lanes 2-3). Therefore, the complete disappearance of
these proteins seen in the absence of protease inhibitors
indicates that there is further degradation in the extracts
which exaggerates the differences between differentiated
and undifferentiated cells. Although, less TBP could be
immunopurified from the MG132 blocked differentiated
cell extracts using the anti-TBP antidody 2C1, when
equal amounts of immunopurified TBP from differenti-
ated and undifferentiated cells was loaded, equivalent
amonts of TAFII135 were detected in the TFIIDs (data
not shown). Thus, while the overall level of TFIID is di-
minished through the reduction in TBP and TAFII135,
the relative stoichiometry of the remaining TFIID is not
significantly altered. The apparently larger decrease in
TAFII135 seen in Fig. 3C results from the lower efficiency
of the antibody (see also Fig. 1C.)
Taken altogether, the above results show that the intrac-
ellular level of TBP and TAFII135 and consequently TFI-
ID is significantly reduced in differentiated cells through
T-RA-induced proteolytic degradation.
Figure 2
Depletion of TBP and TAFII135 is integral to the differentia-
tion process. The positions of TBP and TAFII135 detected by
immunoblotting  are  indicated.  A.  Extracts  were  prepared
from mutant RXRα -/- cells differentiated with T-RA for the
number of days indicated above each lane. B. Control panel
showing  extracts  from  undifferentiated  RXRα -/-  cells.  C.
Immunoblotting  of  extracts  from  T-RA  treated  RXRα -/-
RARγ -/- cells.
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Coordinate degradation of TBP, TAFII135, and the 
RARgamma2 receptor during F9 cell differentiation
It has previously been shown that the RARγ 2 is subject to
degradation beginning 48 hours after T-RA-induced dif-
ferentiation of F9 cells [42]. To determine whether there
is a coordinate degradation of RARγ 2, TBP and
Figure 3
Depletion of TBP and TAFII135 is abrogated in the presence of protease inhibitors MG132 and ALLN. A. Replica plates of cells
were treated with T-RA or vehicle and after 3, 4, 5, 6, and 7 days MG132 was added overnight (12 hours) and extracts then
prepared designated day 4 to day 8 as indicated above each lane. TAFII135, TBP and TAFII55 were detected by immunoblotting.
B. An experiment analogous to that shown in panel A was performed using the protease inhibitor ALLN. C. Measurement of
the intracellular level of TAFII135. In lanes 1-3 cell extracts were made in the absence of MG132. In lanes 4-5 cells were resus-
pended in extraction buffer containing 50 µ M MG132. D. Coordinate degradation of TBP, TAFII135 and the RARγ 2. Cell
extracts were made on the days indicated above each lane from T-RA treated or untreated cells and the presence of TBP,
TAFII135, and the RARγ 2 was detected by immunobloting. The native RARγ  and the phosphorylated species (pRARγ ) are indi-
cated along with a breakdown product indicated by *. A slower migrating species of TAFII135 seen after 48 hours is indicated
by -.
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TAFII135, we examined extracts made at these early
times. After 24 hours of T-RA treament the levels of
RARγ 2, TBP and TAFII135 were unchanged (Fig. 3D,
lanes 1-2). However after 48 hours, there was a T-RA-de-
pendent reduction in the amount of RARγ 2 and TBP and
a significant shift in the electrophoretic mobility of
TAFII135 (lanes 3-4). By 4 days the levels of all three pro-
teins were strongly reduced (lanes 5-6). These results in-
dicate that the onset of degradation of TBP and TAFII135
is concomitant with that of the RARγ 2 suggesting that
these events are interdependent.
Constitutive ectopic expression of TAFII135 impairs F9 cell 
primitive endoderm differentiation
The above results show that the level of TAFII135 and
TBP is strictly controlled during the differentiation of F9
cells by a post-transcriptional mechanism involving tar-
geted proteolysis. To test whether artificially increasing
the level of TAFII135 would affect the proper differentia-
tion of F9 cells, we established cell lines which constitu-
tively express flag-tagged versions of human TAFII135
[fTAFII135(372-1083) and fTAFII135(805-1083) see Ma-
terials and methods]. TAFII135(372-1083) contains all
the known functional domains, but lacks an unconserved
proline-alanine-rich region whereas, TAFII135(805-
1083) comprises only the CR-II region.
For fTAFII135(372-1083) 12 cell lines were examined
and we chose two, lines A and B, since they expressed the
highest levels of the fTAFII135 protein. Immunoblotting
with an anti-flag monoclonal antibody showed a signifi-
cantly higher expression level in line A compared to line
B (Fig. 4A, lanes 1-2). This result is confirmed by immu-
noblotting with monoclonal antibody 20TA which de-
tects both the endogenous and ectopically expressed
TAFII135 proteins (Figs. 4B and 4C, lane 1). In line A, the
level of the ectopically expressed protein is higher than
that of the endogenous protein, while in line B both the
exogenous and the endogenous proteins are expressed at
similar levels. For fTAFII135(805-1083) which contains
only the conserved C-terminal domain, 8 cell lines were
examined of which 3 expressed the fTAFII135 protein
(Fig. 6A). Both of the cell lines expressing
fTAFII135(372-1083) showed an approximately 2-fold
accelerated growth rate compared to wild type cells while
no significant increase was seen in the fTAFII135(805-
1083) expressing cells (Fig. 4E, and data not shown, note
that the apparent slowing of growth between day 8 and
10 for lines A and B is due to their reaching confluence).
We first verified whether treatment of these cells with T-
RA would lead to the depletion of the ectopically ex-
pressed TAFII135. In line A, both the ectopically ex-
pressed TAFII135 and the endogenous TAFII135 were
depleted with the same kinetics (Fig. 4B, lanes 1-5). TBP
was also concomitantly depleted in these extracts, and all
three proteins were stabilised when cells were treated
with MG132 (lanes 6-8). Importantly however, the dis-
appearance of all three proteins was clearly delayed by
48 hours compared to wild-type cells (compare Figs. 4B
and Fig. 1A or Fig. 3C). In line B, there was also coordi-
nate disappearance of TBP and the exogenous and en-
dogenous TAFII135 (Fig. 4C), although no obvious delay
such as that seen in line A is observed. In contrast, no de-
pletion of fTAFII135(805-1083) was seen following T-RA
treatment, while the endogenous TBP and TAFII135 were
depleted normally between days 3 and 5 (Fig. 6B, and
data not shown).
As the targeted proteolysis of TBP and TAFII135 is linked
to the differentiation process, the delayed depletion in
line A suggests that T-RA induced differentiation may be
perturbed. Their differentiation was therefore compared
to that of the wild-type cells.
In wild type cells, the degradation of RARγ 2 begins at day
2 and the protein is strongly depleted from extracts made
at day 3 (Fig. 4D, lane 3). At later times, low levels of only
the unphosphorylated form of RARγ 2 can be seen in the
extracts (lanes 4-6). In contrast, in line A, elevated levels
of RARγ 2 are observed even at day 5 (Fig. 4D, lanes 3-4).
In line B, an intermediate situation is observed since
high levels of RARγ 2 are seen at day 3 which decrease by
day 5 (lanes 3-4). In all cases, low levels of only the un-
phosphorylated RARγ 2 are detected by days 7-9 (lanes 5-
6). These results indicate that proteolytic degradation of
RARγ 2 is delayed in lines A and B suggesting that an ear-
ly event in the differentiation process has been per-
turbed.
Comparison of the growth rate of line A with that of wild-
type cells in the presence of T-RA, shows that line A is
less sensitive to the anti-proliferative effect of T-RA than
wild-type, however growth is eventually slowed com-
pared to undifferentiated cells (Fig. 4E). Line B also
grows faster than wild-type over the first 4-6 days, but
subsequently its growth slows and is considerably re-
tarded compared to undifferentiated cells (Fig. 4E). To-
gether these observations show that line A is poorly
sensitive to T-RA-induced growth arrest and retains an
essentially undifferentiated morphology, while growth of
line B slows after 4-6 days of T-RA treatment and mor-
phological differentiation is retarded.
We determined whether fTAFII135(372-1083) expres-
sion modified T-RA induced apoptosis. The proportion
of early apoptotic cells in lines A, B, and wild-type was
determined by flow cytometry in the presence of propid-
ium iodide and annexin V-FITC [25, 54, 55]. In wild-type
cells, the proportion of early apoptotic cells increasedBMC Molecular Biology (2001) 2:4 http://www.biomedcentral.com/1471-2199/2/4
from 13% in the absence of T-RA to 26% after 5 days of
T-RA treatment (Fig. 5). In line A, spontaneous apopto-
sis was lower than wild type (7% compared to 13%) and
only a mild increase (9%) was seen by day 5 (Fig. 5). In
line B, spontaneous apoptosis was also lower than wild
type (6% compared to 13%), while in the presence of T-
RA the proportion rose to 16% (Fig. 5). Thus, line A is re-
sistant to T-RA induced apoptosis, while line B shows re-
duced sensitivity to T-RA induced apoptosis.
Differentiation of lines A and B was further assessed
from changes in cellular morphology. 6-8 days after the
addition of T-RA, wild-type F9 cells adopt a typical flat-
tened primitive endodermal morphology (see upper pan-
el of Fig. 7). In contrast, line A cells retain an essentially
undifferentiated morphology even after 8 days of T-RA
treatment (centre panel Fig. 7). The differentiation of
line A is severely impaired, as the cells never adopt a dif-
ferentiated morphology even after 10-12 days of RA-
treatment (data not shown). Similarly, line B cells appear
Figure 4
Characterisation of F9 cell lines A and B expressing ectopic f TAFII135(372-1083). A. The presence of f TAFII135(372-1083) in
extracts from each cell line was determined using the commercial anti-flag monoclonal antibody. B. Immunoblot analysis of
extracts from line A differentiated for the number of days indicated above each. Lanes 6-8 show extracts from cells treated for
12 hours with MG132. C. Immunoblot analysis of differentiated cell extracts from line B. D. Immunoblot analysis of extracts
from wild-type cells and lines A and B with antibodies against RARγ 2. The native and phosphorylated species and the break-
down product are indicated as in Fig. 4D. E. Cell growth was measured for 10 days in the presence or absence of T-RA. The
cell number is indicated on the X axis and the number of days of growth is indicated on the Y axis. Analogous results were
obtained in three independent experiments and the graph shows the results of a representative experiment.
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essentially undifferentiated after 6 days of T-RA treat-
ment (lower panel, Fig. 7). After 8 days, a fraction of the
cells begin to adopt a primitive endodermal type mor-
phology, although the cells are much less flattened than
wild-type cells, and the majority of the cells retain an un-
differentiated morphology (Fig. 7). Only after 10 days of
T-RA treatment did the majority of the cells adopt a dif-
ferentiated morphology (data not shown).
F9 cell differentiation is characterised by the induction of
different marker genes. We used reverse transcription
coupled-PCR (RT-PCR) to compare the induction of
some of these genes in lines A and B with that observed
in wild-type cells. The RARβ 2 gene is a marker which is
rapidly induced in wild-type cells normally, after 12-24
hours [495051, 56]. In agreement with this, the RARβ 2
mRNA is fully induced by day 3 in wild-type cells. Ex-
pression persists until day 5 and decreases only by day 7
(Fig. 8A, lanes 2-5, note that the small increase in lane 5
in this experiment is not reproducibly observed). In con-
trast, in lines A and B, RARβ 2 expression is weak at day
3, peaks only at day 5, and drops off by day 7 (lanes 7-10
and 12-15). Thus, induction of RARβ 2 is severely retard-
ed and transient in lines A and B. In the same RNA sam-
ples, constant expression levels of HPRT were observed
in differentiated and undifferentiated cells. In contrast to
the RARβ 2 gene, induction of the collagen IVα 1 and lam-
inin B1 mRNAs was almost identical in the wild-type and
mutant cells (Fig. 8B and data not shown) showing that
the delay in induction is specific to RARβ 2.
Figure 5
Detection of early apoptotic cells by flow cytometry. The
percentage of early apoptotic cells in  undifferentiated cul-
tures and in day 5 T-RA-differentiated cultures is indicated
for wild type cells and for lines A and B.
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Figure 6
Isolation  and  analysis  of  cells  expressing  fTAFII135(805-
1083). A. Extracts from wild-type cells and 5 different clones
were analysed by immunoblotting using an anti-flag antibody.
B Extracts were made from clone 2 cells differentiated with
T-RA for the number of days indicated above each lane. The
fTAFII135(805-1083) deletion mutant was detected in the cell
extracts using the anti-flag antibody.
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After 6 days of T-RA treatment, bt2cAMP was added to
induce parietal endoderm differentiation. Addition of
bt2cAMP induced the rapid appearance of rounded cells
with typical parietal endoderm morphology for both the
wild type cells and lines A and B (Fig. 9). Thus, while
primitive endoderm differentiation of lines A and B is
impaired, they readily differentiate into parietal endo-
derm.
In lines A and B, we noticed after 6-8 days of T-RA treat-
ment the appearance of a novel cell type characterised by
elongated tightly packed cells (Fig. 10A). The morpholo-
gy of these cells was completely different from those of
undifferentiated or primitive endoderm cells. Although
the majority of the cell population differentiates when
bt2cAMP is added to these cultures, the elongated cells
persisted even after several days of bt2cAMP treatment
(Fig. 10B) showing that these cells are refractory to the
differentiating effect of bt2cAMP. Cells with this atypical
morphology were not observed when wild-type cells or
fTAFII135(805-1083) expressing cells are differentiated
either with T-RA or T-RA and bt2cAMP. Therefore, ec-
topic expression of fTAFII135(372-1083) has induced a
novel differentiation pathway leading to the appearance
of atypical elongated cells.
Taken altogether, the above results show that primitive
endoderm differentiation of F9 cells is blocked in line A
expressing the highest level of TAFII135(372-1083) and
is significantly retarded in line B cells which express low-
er levels of TAFII135(372-1083). In contrast, all three
fTAFII135(805-1083) expressing cell lines and several
control lines picked at the same time all showed a normal
T-RA response with respect to growth inhibition, differ-
entiated cell morphology, and targeted depletion of
TAFII135 and TBP (Fig. 6B and data not shown).
TAFII135 and TBP are depleted in extracts from differenti-
ated C2C12 cells
To determine whether the down regulation of TBP and
TAFII135 is specific to F9 cell differentiation we asked
whether this phenomenon could be observed in an unre-
lated cell type. C2C12 are mouse skeletal muscle myob-
lasts which differentiate into multinucleated myotubes
[57]. This differentiation process does not require the ad-
dition of retinoic acid, but takes place spontaneously
Figure 7
Morphology of lines A and B in the presence of T-RA. A. Each panel shows representative phase-contrast photography at 125-
fold magnification of wild-type cells or lines A and B after the indicated number of days treatment with T-RA.
Cell line -T-RA +T-RA Day 6 +T-RA Day 8
WT
A
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when cultures are grown to high density and undergo
growth arrest.
In extracts from differentiating C2C12 cells, a progres-
sive decrease in TAFII135 and TBP can be seen beginning
on day 6 such that these proteins are strongly depleted
from the extracts by day 11 (Fig. 11A, lanes 1-5 compare
with lane 6). In contrast, the levels of TAFII55 remain
constant (Fig. 11A). The observed depletion of TBP and
TAFII135 was not observed when the cells on day 10 were
treated with MG132 for 12 hours prior to extract prepa-
ration on day 11 (Fig. 11B, lanes 1-3). These results indi-
cate that TBP and TAFII135 are also targetted for
proteolytic degradation during C2C12 cell differentia-
tion.
Discussion
Post-transcriptional regulation of TAFII135 and TBP in dif-
ferentiated F9 cells
We show here that targeted proteolysis of TBP and
TAFII135 is an integral part of the T-RA response in F9
cells. This process is specific for TBP and TAFII135 as it
is not observed with the other TFIID components ana-
lysed, and is induced concomitantly with that of the
RARγ 2. In F9 cells with constitutive ectopic expression of
TAFII135, targeted degradation is delayed, primitive en-
dodermal differentiation is impaired and a novel differ-
entiation pathway is induced. Hence, targeted
degradation of TAFII135 and TBP is a prerequisite for
proper F9 celll differentiation.
TAFII135 and TBP progressively disappear from whole
cell or nuclear extracts made from T-RA differentiated
F9 cells. This depletion does not result from altered tran-
scription of these genes, since no significant changes in
the corresponding mRNA levels were observed during
differentiation. In lines A and B, the ectopic expression
of f-TAFII135 is driven by a synthetic promoter, yet coor-
dinate depletion of the exogenous and endogenous
TAFII135 is observed further confirming that this is in-
deed a post-transcriptional event.
Figure 8
RT-PCR analysis of gene expression during differentiation. A. Delayed induction of the RARβ 2 gene. Aliquots of the PCR reac-
tions made with RNA from the day shown above each lane were electrophoresed, blotted, and hybridised with an internal oli-
gonucleotide probe for the RARβ 2 gene. B. Aliquots of the PCR reactions performed with the same RNA samples as in panel
A were analysed by electrophoresis on an agarose gel and staining with ethidium bromide.
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In contrast, TBP and TAFII135 are readily detected in ex-
tracts made from differentiated cells treated with
MG132, ALLN, and the proteasome-specific inhibitor
lactacystin (our unpublished data) showing that their
disappearance is due to selective proteolysis. In the pres-
ence of the inhibitors, the detected levels are significant-
ly lower than those seen in equivalent extracts made
from undifferentiated cells. Addition of the protease in-
hibitors only during the extraction procedure is another
way to measure of the intracellular level of TBP and
TAFII135. In these extracts also, the levels of TBP and
TAFII135 are significantly reduced in differentiated cells
compared with undifferentiated cells. Therefore, the in-
tracellular levels of TBP and TAFII135 and consequently
TFIID are reduced in differentiated cells through selec-
tive proteolysis.
Targeted degradation of TAFII135 does not require ami-
no acids 1-372 since deletion mutant (372-1083) is tar-
geted along with the endogenous protein in lines A and
B. In contrast, mutant (805-1083) is not degraded dur-
ing differentiation indicating that the sequences re-
quired for targeting are located between amino acids
372-805. Many of proteins which are targeted for prote-
olytic degradation contain signal sequences such as
PEST or cyclin destruction boxes which mediate their
proteolysis, however no recognised destabilising motifs
are present in TBP and TAFII135 and indeed these pro-
teins are stable in non-differentiated F9 cells and in
many other cell types. It will therefore be interesting to
identify the sequences are required for degradation of
TBP and TAFII135 in differentiating F9 cells. In this re-
spect we note that we have not been able to recover F9
cell lines significantly overexpressing TBP suggesting
that TBP overexpression is toxic.
Figure 9
Parietal differentiation of lines A and B. Each panel shows
representative phase-contrast photography at 125-fold mag-
nification of wild-type cells or lines A and B after 6 days of
treatment with T-RA and two days with T-RA and bt2cAMP.
Cell line +T-RA +bt2cAMP Day 8
WT
A
B
Figure 10
Abberant differentiation of lines A and B in the presence of
T-RA. A. Phase contrast photograph of line B cells differenti-
ated with T-RA showing the presence of elongated fibrob-
last-like cells. B. Phase contrast photograph of line A cells
differentiated with T-RA and bt2cAMP. The rounded parietal
endoderm cells can be seen alongside cells with an elongated
morphology.
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In F9 cells, RARγ 2 plays a key role in primitive endoderm
differentiation [5859]. 48 hours after addition of T-RA
degradation of this protein begins such that by 3-4 days
most of the protein is depleted [42]. The onset of RARγ 2
degradation coincides with that of TBP and TAFII135
suggesting that these events are causaly related. This
idea is supported by the fact that in line A degradation of
TBP, TAFII135, and RARγ 2 are all delayed to similar ex-
tents. A lesser delay in degradation of RARγ 2 in line B
was also observed. If the corresponding delay in TBP and
TAFII135 degradation in line B was less than two days, it
would be missed since we prepared extracts at two day
intervals. All of these observations are consistent with
the idea that upon exposure to T-RA there is an early
transcriptional response in which a RARγ 2/RXR het-
erodimer activates genes required for differentiation. As
a consequence, the RARγ 2, and the TAFII135 and TBP
components of the basal transcription machinery are
down-regulated through proteolytic degradation. It has
been suggested that degradation of the RARγ 2 or the ER
is a means of regulating the cellular response to these lig-
ands both in terms of magnitude and time [42, 44]. The
coordinate degradation of RARγ 2, TBP, and TAFII135 in
response to T-RA indicates that the cellular T-RA re-
sponse is not only regulated through degradation of the
activator, but also through degradation of components of
the basal transcription machinery.
The differentiation of C2C12 myoblasts into myotubes
does not require T-RA, but is induced by growth inhibi-
tion and serum starvation. Despite the important differ-
ences between these cells and F9 cells, targeted
degradation of TBP and TAFII135 is also observed when
C2C12 cells differentiate. Hence, targeted degradation
can be induced by stimuli other than T-RA. Our report is
the first showing that basal transcription factors can be
regulated in this way in response to different physiologi-
cal stimuli.
As described in the Introduction, recent studies indicate
that the activation process is linked to targeted proteoly-
sis of transcriptional activators. In the case of the RARγ 2,
degradation requires a constitutive phosphorylation of
the AF-1 domain, heterodimerisation with RXR, and the
presence of ligand indicating that the receptor has to be
transcriptionally active to be degraded [42]. Under these
conditions the receptor is ubiquitinated and degraded.
While we have not been able to directly detect ubiquiti-
nation of TBP or TAFII135 in extracts where ubiquitina-
tion of RARγ 2 can be detected (our unpublished data), at
early times we do observe a significant shift in the elec-
trophoretic mobility of TAFII135 which may correspond
to a polyubiquitinated intermediate While the molecular
events involved in degradation of transcription factors
are in general poorly understood, it is noteworthy that
both NRs and TBP have been reported to interact with
the proteasome component SUG1 [6061] which may act
Figure 11
Depletion of TBP and TAFII135 in extracts from differentiated C2C12 cells. A. Immunoblot analysis of extracts from C2C12
cells grown at high density in the absence of serum for the number of days indicated above the panel. B. Immunoblot analysis
of extracts from C2C12 cells in the presence or absence of MG132 added at day 10 and extracts prepared on day 11. Lanes 2
and 3 show duplicate extracts from two dufferent paltes treated with MG132.
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to target these proteins for degradation. In addition, oth-
er components of the proteasome/ubiquitin degradation
pathway have also been shown to interact with either nu-
clear receptors or components of the preinitiation com-
plex (for review see [38]). Further experiments will be
required to determine whether TBP and TAFII135 are
modified directly to allow targeting, or whether they are
targeted indirectly through the formation of transcrip-
tionally active complexes with the RARγ 2 which, as it is
itself degraded, acts to recruit the degradation machin-
ery.
A decreased level of TBP in differentiated F9 cells has
previously been noted [62,63]. These studies did not ad-
dress the mechanism underlying its down-regulation,
but they revealed a down-regulation of the pol III TAF
BRF and the pol I TAFI48 and TAFI95 proteins and di-
minished transcription by the corresponding polymeras-
es in T-RA differentiated F9 cells. In the light of the
present study, it is possible that the BRF, TAFI48, and
TAFI95 proteins are also post-transcriptionally down-
regulated by targeted proteolysis in the same way as TBP
and TAFII135. This pathway may therefore be used to
more generally regulate the activity of all three RNA
polymerases during differentiation.
TAFII135 plays a key role in F9 cell growth and differentia-
tion
We show here that T-RA-induced primitive endoderm
differentiation is impaired in cell lines constitutively ex-
pressing ectopic TAFII135(372-1083) as judged from, re-
tarded targeted degradation of RARγ 2, cell morphology,
growth inhibition, apoptotic response, and induction of
the RARβ 2 marker gene. The effects are most pro-
nounced in line A cells which express the highest level of
ectopic TAFII135 and do not show a differentiated cell
morphology even upon prolonged exposure to T-RA. An
intermediate, but significant, effect is seen using all cri-
teria tested in line B cells, where fTAFII135(372-1083)
expression is lower. In contrast, cells expressing
fTAFII135(805-1083) differentiate normally.
The RARβ 2 gene is normally fully induced by 12-24
hours [56] and elevated expression persists up until day
5. In lines A and B, induction was seen only after 5 days
and this induction was transient compared to wild-type
cells. As the RARβ 2 gene is important for T-RA-induced
growth arrest [64], its delayed induction in lines A and B
may in part explain the phenotype of these cells. Never-
theless, the collagen IVα 1 and laminin B1 genes (as well
as several other known marker genes, our unpublished
data), are induced normally in lines A and B by day 3-5
even when no obvious morphological differentiation is
observed. This differential induction of the RARβ 2 ver-
sus other marker genes has not been previously noted in
the various RAR and RXR knock out cell lines analysed.
The phenotype generated by ectopic TAFII135 expres-
sion is therefore distinct from that seen in these knock
out cell lines. Most of the currently identified marker
genes are not appropriate for the analysis of the pheno-
type of these lines. A detailed understanding of how ec-
topically expressed TAFII135 blocks primitive endoderm
differentiation will require the identification of novel
marker genes whose expression is significantly altered in
lines A and B and which may be directly regulated by
TAFII135.
Despite the fact that primitive endoderm differentiation
of these lines is perturbed, they differentiate normally
into parietal endoderm. This shows that, in contrast to
what has previously been assumed, differentiation into
parietal endoderm does not require the cells to first be
fully differentiated into primitive endoderm since line A
cells go from an essentially undifferentiated morphology
to a parietal morphology. However, even line A is not to-
tally refractory to T-RA, since several marker genes are
induced and they have become bt2cAMP responsive.
Again, the phenotype of these cells is not the same as that
of the RXRα -/-RARγ -/- cells where none of these events
take place.
Our results rather indicate that ectopic TAFII135 expres-
sion acts at an early stage to impair primitive endoderm
differentiation, but does not prevent the T-RA-induced
changes which render the cells bt2cAMP responsive. The
initial elevated TAFII135 expression in lines A and B im-
pairs both the T-RA transcriptional response and its as-
sociated degradation of RARγ 2, TBP, and TAFII135
prolonging the period of elevated expression of these
proteins resulting in a subsequent block of primitive en-
doderm differentiation. It has previously been shown
that phosphorylation of the RARγ 2 AF-1 is indispensable
for primitive endoderm differentiation [59]. When F9
cells expressing the RARγ 2 in which the phosphorylation
site has been mutated are treated with T-RA, no degrada-
tion of this protein is observed. There is therefore an in-
timate relationship between differentiation and RARγ 2
degradation suggesting that proper RARγ 2 degradation
is essential for differentiation [42]. This idea is support-
ed by our present results since we show that TAFII135
overexpression impairs both RARγ 2 degradation and
primitive endoderm differentiation. It is therefore prob-
able that the increased stability of the RARγ 2 in lines A
and B is the major cause of their impaired primitive en-
doderm differentiation. It is interesting to note that the
TAFII135(805-1083) deletion mutant is not degraded in
response to T-RA and its expression does not interfere
with differentiation. This suggests that TAFII135 is only
targeted for degradation if it contributes functionally to
the T-RA response.BMC Molecular Biology (2001) 2:4 http://www.biomedcentral.com/1471-2199/2/4
The severity of the phenotype observed in lines A and B
correlates with the expression level of the exogenous f
TAFII135(372-1083) protein, a version of TAFII135 in
which the N-terminal proline-alanine rich region has
been deleted. The deleted region is not conserved in
hTAFII105 and dTAFII110, is not involved in interactions
with other TAFIIs, SP1, or CREB [26,27, 33], and has no
known function. In agreement with this, the
fTAFII135(372-1083) [and the fTAFII135(805-1083)]
protein can be coprecipitated with the endogenous TFI-
ID of lines A and B (our unpublished data). It is likely
therefore that the phenotype of lines A and B results
from the TAFII135 overexpression per se, although we
cannot exclude the possibility that the effects are not due
only to the elevated expression levels, but that they may
additionally reflect a dominant negative property of this
mutant. Investigation of this has been hampered by the
fact that we have not been able to isolate F9 cell lines sta-
bley expressing full length TAFII135.
Treatment of lines A and B with T-RA induces a fraction
of the cells to adopt an atypical elongated cell morpholo-
gy, which to our knowledge has not been previously seen
upon differentiation of F9 cells. Unlike the other cells in
the population, these cells do not differentiate into pari-
etal endoderm showing that they are refractory to
bt2cAMP. These observations suggest that ectopic
TAFII135 expression promotes T-RA induction of genes
which are normally not activated in F9 cells leading to a
novel differentiation pathway. It is also possible that
TAFII135 expression modulates the activity of transcrip-
tion factors in addition to the RARs leading to the ap-
pearance of this novel cell type.
Conclusions
We report for the first time that components of the basal
transcription machinery are subject to regulation by tar-
geted proteolysis in response to a physiological stimulus.
Our results point to a critical role of TAFII135 in F9 cell
physiology. It is downregulated during F9 cell differenti-
ation and expression of TAFII135 at elevated levels pro-
motes cell growth, impairs the normal T-RA response,
and induces a novel differentiation pathway.
Materials and methods
F9 and C2C12 cell culture and differentiation
Wild-type and mutant F9 cells were grown as described
[25, 49]. Differentiation was induced by addition of 1.0
µ M all-trans retinoic acid (T-RA) with or without 250 µ M
di-butaryl bt2cAMP. In most experiments an appropriate
number of 10 cm plates were seeded with 105 cells and af-
ter 24 hours (day 0) T-RA was added and protein or RNA
extracts were made from one plate of cells on each of the
indicated days. Stably transformed cell lines were isolat-
ed by electroporating plasmid pXJ-fTAFII135(372-1083)
along with the puromycin resistance gene under the con-
trol of the SV40 promoter. Puromycin resistant cell
clones were selected in the presence of 1µ g/ml of puro-
mycin, amplified, and the presence of exogenous
fTAFII135(372-1083) was detected by immunoblotting
and immunofluoresence (data not shown). Aliquots of
each clone were frozen after the minimum number of
passages and three independent differentiation experi-
ments giving analogous results were started from the fro-
zen stocks. For cell growth rates, 3 cm plates were seeded
with 103 cells and after 4-10 days cells were counted with
a particle counter (Coulter Z2). C2C12 cells were main-
tained undifferentiated by growth at low density. C2C12
cells were differentiated by plating at high density and
growth in 0.1% serum for the number of days indicated
on the figures. Morphological differentiation was clearly
seen by light microscopy.
Extract preparation and immunoblotting
Protein extracts from cells were made essentially as pre-
viously described [4, 65]. Briefly, cells were washed and
harvested with ice cold phosphate buffered saline. Cells
were then resuspended in buffer A (50 mM Tris-HCl pH
7.5, 20% glycerol, 1 mM Dithiothreitol, 0.2% Nonidet P-
40) with 0. 5 M KCl and subjected to two rounds of
freeze-thaw followed by a 30 min incubation on ice. The
cell debris was then removed by centrifugation and the
soluble protein fraction was frozen in liquid nitrogen and
stored at -80° C. Nuclear extracts were prepared by first
lysing the cells for 10 minutes in 1 ml of isotonic buffer
(50 mM KCl, 50 mM Tris-HCl, pH 7.9, 0.2% NP40, 0.5
mM EDTA and 1.5 mM MgCl2). The nuclei were then re-
covered by centrifugation at 2000 rpm for 5 minutes and
the supernatant containing the cytoplasmic proteins was
discarded. Nuclear protein was then extracted from the
purified nuclei with buffer A containing 1.0 M KCl. Pro-
tein concentrations were determined by the method of
Bradford using a Biorad protein assay kit. Equal
amounts of protein, normally 10 µ g unless otherwise
stated, were then subjected to SDS PAGE and immunob-
lotting. TBP was detected using monoclonal antibodies
3G3 and 2C1 [666768]. TAFII135 was detected using
monoclonal antibody 20TA [5] which recognizes an
epitope in the conserved C-terminal domain and mono-
clonal antibody 32TA raised against peptide P1 in the N-
terminal region as described in [5]. TAFII100, TAFII55,
TAFII30, and TAFII20, were detected using the previous-
ly described monoclonal antibodies ([4, 69, 70] and refs
therein). RARγ 2 was detected using the previously de-
scribed antibody [42]. Anti-flag monoclonal antibody
was puchased from Sigma. Blots were revealed using
peroxidase conjugated goat anti-mouse IgG antibody
and chemiluminescence with an ECL kit (Amersham).
Protease inhibitors MG132 (Cbz-leu-leu-leucinal) and
ALLN (acetyl-leu-leu-norleucinal) were purchased fromBMC Molecular Biology (2001) 2:4 http://www.biomedcentral.com/1471-2199/2/4
CalBiochem and ICN Biochemicals respectively. Each
was resuspended in DMSO and added to cells or extracts
at a final concentration of 50 µ M.
RT-PCR and flow cytometry
Total cellular RNA was isolated using Trizol Reagent
(Life Technologies) from F9 cells grown in parallel with
those used for making protein extracts. 1 µ g of total RNA
was then analysed by RT-PCR performed as described
[50] Control reactions (not shown) contained all compo-
nents except reverse transcriptase. Details of the exon-
specific primers for HPRT, TBP, and TAFII135, are avail-
able upon request. The primers used for RARβ 2, laminin
B1 and collagen IVa1 were as previously described [49].
Southern blotting and hybridisation for RARβ 2 were
performed by standard procedures. Flow cytometry was
performed as described by Metzger et al., (1999) using a
final concentration of 25 µ g/ml of propidium iodide and
FITC-labelled annexin V (CALTAG Laboratories). Sam-
ples were analysed on a FACScan (Becton Dickinson)
equipped with a single aron laser. A minimum of 105 cells
per sample were analysed with the CELLQuest software.
Acknowledgements
We thank D. Metzger and F.Cammas for providing the RXR/RAR mutant 
cell lines and for advice on F9 cell culture and differentiation, C. Egly for 
help with RARγ 2 and discussion, C. Waltzinger, for help with flow cytom-
etry, M. Abrink and Y-G. Gangloff for critical reading of the manscript, S. 
Vicaire and D. Stephane for DNA sequencing, the monoclonal antibody fa-
cility, the staff of cell culture and oligonucleotide facilities, B. Boulay, J.M. La-
fontaine, and C. Werlé for illustrations, L.P was supported by a Marie Curie 
EU fellowship and E.K. by fellowships from the Fondation Chateaubriand 
and INSERM. This work was supported by grants from the CNRS, the IN-
SERM, the Hôpital Universitaire de Strasbourg, the Ministère de la Recher-
che et de la Technologie, the Association pour la Recherche contre le 
Cancer, the Ligue Nationale contre le Cancer, and the Human Frontier Sci-
ence Programme.
References
1. Burley SK, Roeder RG: Biochemistry and structural biology of
transcription  factor  IID  (TFIID).  Annu.  Rev.  Biochem  1996,
65:769-799
2. Bell  B,  Tora  L: Regulation  of  Gene  Expression  by  Multiple
Forms of TFIID and Other Novel TAFII-Containing Com-
plexes. Exp. Cell Res 1999, 246:11-19
3. Albright  SR,  Tjian  R: TAFs  revisited:  more  data  reveal  new
twists and confirm old ideas. Gene 2000, 242:1-13
4. Mengus G, May M, Jacq X, Staub A, Tora L, Chambon P, Davidson I:
Cloning  and  characterization  of  hTAFII18,  hTAFII20  and
hTAFII28: three subunits of the human transcription factor
TFIID. EMBO J 1995, 14:1520-1531
5. Mengus  G,  May  M,  Carre  L,  Chambon  P,  Davidson  I:  Human
TAFII135 potentiates transcriptional activation by the AF-2s
of the retinoic acid, vitamin D3, and thyroid hormone recep-
tors in mammalian cells. Genes Dev 1997, 11:1381-1395
6. Georgieva S, Kirschner DB, Jagla T, Nabirochkina E, Hanke S, Schen-
kel H, de Lorenzo C, Sinha P, Jagla K, Mechler B: Two novel dro-
sophila TAFIIs have homology with human TAFII30 and are
differentially regulated during development. Mol Cell Biol 2000,
20:1639-48
7. Moqtaderi Z, Yale JD, Struhl K, Buratowski S:  Yeast homologues
of higher eukaryotic TFIID subunits. Proc. Natl. Acad. Sci. U.S.A
1996, 93:14654-14658
8. Wieczorek E, Brand M, Jacq X, Tora L:  Function of TAFII-contain-
ing complex without TBP in transcription by RNA polymer-
ase II. Nature 1998, 393:187-191
9. Brand M, Yamamoto K, Staub A, Tora L: Identification of TATA-
binding protein-free TAFII-containing complex subunits sug-
gests a role in nucleosome acetylation and signal transduc-
tion. J. Biol. Chem 1999, 274:18285-18289
10. Grant PA, Schieltz D, Pray-Grant MG, Steger DJ, Reese JC, Yates JR,
Workman JL: A subset of TAFIIs are integral components of
the SAGA complex required for nucleosome acetylation and
transcriptional stimulation. Cell 1998, 94:45-53
11. Ogryzko VV, Kotani T, Zhang X, Schlitz RL, Howard T, Yang XJ,
Howard BH, Qin J, Nakatani Y: Histone-like TAFs within the
PCAF histone acetylase complex. Cell 1998, 94:35-44
12. Martinez E, Kundu TK, Fu J, Roeder RG: A human SPT3-TAFII31-
GCN5-L acetylase complex distinct from transcription fac-
tor IID. J. Biol. Chem 1998, 273:23781-23785
13. Michel B, Komarnitsky P, Buratowski S: Histone-like TAFs are es-
sential for transcription in vivo. Mol. Cell 1998, 2:663-673
14. Komarnitsky  PB,  Michel  B,  Buratowski  S:  TFIID-specific  yeast
TAF40 is essential for the majority of RNA polymerase II-
mediated transcription in vivo. Genes. Dev 1999, 13:2484-2489
15. Sanders SL, Klebanow ER, Weil PA: TAF25p, a non-histone-like
subunit of TFIID and SAGA complexes, is essential for total
mRNA gene transcription in vivo. J. Biol. Chem 1999, 274:18847-
18850
16. Apone LM, Virbasius CA, Holstege FC, Wang J, Young RA, Green MR:
Broad,  but  not  universal,  transcriptional  requirement  for
yTAFII17, a histone H3-like TAFII present in TFIID and SA-
GA. Mol. Cell 1998, 2:653-661
17. Moqtaderi Z, Keaveney M, Struhl K: The histone H3-like TAF is
broadly  required  for  transcription  in  yeast.  Mol.  Cell  1998,
2:675-682
18. Walker  SS,  Shen  WC,  Reese  JC,  Apone  LM,  Green  MR:  Yeast
TAFII145 required for transcription of G1/S cyclin genes and
regulated by the cellular growth state. Cell 1997, 90:607-614
19. Apone LM, Virbasius CM, Reese JC, Green MR: Yeast TAFII90 is
required for cell-cycle progression through G2/M but not for
general transcription activation. Genes. Dev 1996, 10:2368-2380
20. Green MR: TBP-associated factors (TAFIIs): multiple, selec-
tive transcriptional mediators in common complexes. Trends
Biochem Sci 2000, 25:59-63
21. Sekiguchi T, Nohiro Y, Nakamura Y, Hisamoto N, Nishimoto T: The
human  CCG1  gene,  essential  for  progression  of  the  G1
phase, encodes a 210-kilodalton nuclear DNA-binding pro-
tein. Mol Cell Biol 1991, 11:3317-25
22. Suzuki-Yagawa Y, Guermah M, Roeder RG: The ts13 mutation in
the TAFII250 subunit (CCG1) of TFIID directly affects tran-
scription of D-type cyclin genes in cells arrested in G1 at the
nonpermissive temperature. Mol. Cell Biol 1997, 17:3284-3294
23. Wang EH, Tjian R: Promoter-selective transcriptional defect in
cell cycle mutant ts13 rescued by hTAFII250. Science 1994,
263:811-814
24. O'Brien T, Tjian R: Different functional domains of TAFII250
modulate  expression  of  distinct  subsets  of  mammalian
genes. Proc Natl Acad Sci U S A 2000, 97(6):2456-61
25. Metzger D, Scheer E, Soldatov A, Tora L: Mammalian TAFII30 is
required for cell cycle progression and specific cellular differ-
entiation programmes. EMBO J. 1999, 18:4823-4834
26. Saluja D, Vassallo MF, Tanese N: Distinct subdomains of human
TAFII130 are required for interactions with glutamine-rich
transcriptional activators. Mol. Cell Biol 1998, 18:5734-5743
27. Tanese N, Saluja D, Vassallo MF, Chen JL, Admon A: Molecular
cl o ni n g  an d a na ly s i s  of  t wo s u bu ni t s  of  th e  hu man  TF I I D
complex: hTAFII130 and hTAFII100. Proc. Natl. Acad. Sci. U.S.A
1996, 93:13611-13616
28. Nakajima T, Uchida C, Anderson SF, Parvin JD, Montminy M: Analy-
sis of a cAMP-responsive activator reveals a two-component
mechanism for transcriptional induction via signal-depend-
ent factors. Genes Dev 1997, 11:738-747
29. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse
S, Kimura T, Koide R, Nozaki K, Sano Y: Expanded polyglutamine
stretches interact with TAFII130, interfering with CREB-de-
pendent transcription. Nat Genet 2000, 26:29-36
30. Dikstein R, Zhou S, Tjian R: Human TAFII105 is a cell type-spe-
cific TFIID subunit related to hTAFII130. Cell 1996, 87:137-146
31. Reese JC, Zhang Z, Kurpad H: Identification of a yeast transcrip-
tion  factor  IID  subunit,  TSG2/TAF48.  J  Biol  Chem  2000,
275:17391-8BMC Molecular Biology (2001) 2:4 http://www.biomedcentral.com/1471-2199/2/4
32. Sanders SL, Weil PA: Identification of two novel TAF subunits
of the yeast saccharomyces cerevisiae TFIID complex. J Biol
Chem 2000, 275:13895-900
33. Gangloff YG, Werten S, Romier C, Carre L, Poch O, Moras D, Dav-
idson  I:  The  human  TFIID  components  TAFII135  and
TAFII20  and  the  yeast  SAGA  components  ADA1  and
TAFII68 heterodimerize to form histone-like pairs. Mol Cell
Biol 2000, 20:340-351
34. Gangloff YG, Romier C, Thuault S, Werten S, Davidson I: The his-
tone fold is a key structural motif of transcription factor TFI-
ID. Trends Biochem. Sci. 2001, 26:250-257
35. Molinari E, Gilman M, Natesan S: Proteasome-mediated degra-
dation of transcriptional activators correlates with activa-
tion domain potency in vivo. EMBO J 1999, 18:6439-47
36. Salghetti SE, Muratani M, Wijnen H, Futcher B, Tansey WP: Func-
tional overlap of sequences that activate transcription and
signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci U S A
2000, 97:3118-23
37. Salghetti SE, Kim SY, Tansey WP: Destruction of Myc by ubiqui-
tin-mediated proteolysis: cancer-associated and transform-
ing mutations stabilize Myc. EMBO J 1999, 18:717-26
38. Thomas D, Tyers M: Kamikaze activators. Curr Biol 2000, 10:341-3
39. El Khissiin A, Leclercq G: Implication of proteasome in estrogen
receptor degradation. FEBS Lett 1999, 448:160-6
40. Lange CA, Shen T, Horwitz KB: Phosphorylation of human pro-
gesterone receptors at serine-294 by mitogen-activated pro-
tein kinase signals their degradation by the 26S proteasome.
Proc Natl Acad Sci U S A 2000, 97:1032-7
41. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW: Protea-
some-dependent degradation of the human estrogen recep-
tor. Proc Natl Acad Sci U S A 1999, 96:1858-62
42. Kopf E, Plassat JL, Vivat V, de The H, Chambon P, Rochette-Egly C:
Dimerization with RXRs and phosphorylation modulate the
retinoic  acid-  induced  degradation  of  RAR{alpha}  and
RAR{gamma} and through the ubiquitin-proteasome path-
way. J Biol Chem 2000, 275:33280-8
43. Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, Quignon
F, Rochette-Egly C, de The H: Retinoic acid induces proteasome-
dependent degradation of retinoic acid receptor alpha (RA-
Ralpha) and oncogenic RARalpha fusion proteins. Proc Natl
Acad Sci U S A 1999, 96:14807-12
44. Lonard DM, Nawaz Z, Smith CL, O'Malley BW: The 26S proteas-
ome is required for estrogen receptor-alpha and coactivator
turnover and for efficient estrogen receptor-alpha transacti-
vation. Mol Cell 2000, 5:939-48
45. Kim TK, Maniatis T: Regulation of interferon-gamma-activated
STAT1 by the ubiquitin-proteasome pathway. Science 1996,
273:1717-9
46. Mathew A, Mathur SK, Morimoto RI: Heat shock response and
protein degradation: regulation of HSF2 by the ubiquitin-
proteasome pathway. Mol. Cell. Biol. 1998, 18:5091-8
47. Strickland S, Mahdavi V: The induction of differentiation in ter-
atocarcinoma stem cells by retinoic acid. Cell 1978, 15:393-403
48. Strickland S, Smith KK, Marotti KR: Hormonal induction of differ-
entiation in teratocarcinoma stem cells: generation of pari-
etal endoderm by retinoic acid and dibutyryl cAMP. Cell 1980,
21:347-355
49. Clifford J, Chiba H, Sobieszczuk D, Metzger D, Chambon P: RXRal-
pha-null F9 embryonal carcinoma cells are resistant to the
differentiation,  anti-proliferative  and  apoptotic  effects  of
retinoids. EMBO J 1996, 15:4142-4155
50. Chiba H, Clifford J, Metzger D, Chambon P: Distinct retinoid X re-
ceptor retinoic acid receptor heterodimers are differentially
involved in the control of expression of retinoid target genes
in F9 embryonal carcinoma cells. Mol. Cell Biol 1997, 17:3013-
3020
51. Chiba H, Clifford J, Metzger D, Chambon P: Specific and redun-
dant functions of retinoid X Receptor/Retinoic acid receptor
heterodimers in differentiation, proliferation, and apoptosis
of F9 embryonal carcinoma cells. J. Cell Biol 1997, 139:735-747
52. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D,
Goldberg AL: Inhibitors of the proteasome block the degrada-
tion of most cell proteins and the generation of peptides pre-
sented on MHC class I molecules. Cell 1994, 78:761-771
53. Lee  DH,  Goldberg  AL:  Proteasome inhibitors: valuable new
tools for cell biologists. Trends. Cell Biol 1998, 8:397-403
54. Lecoeur H, Gougeon ML: Comparative analysis of flow cyto-
metric methods for apoptosis quantitation in murine thymo-
cytes and human peripheral lymphocytes from controls and
HIV-infected persons. Evidence for interference by granulo-
cytes  and  erythrocytes.  Journal of Immunological Methods 1996,
198:87-99
55. Philippe J, Louagie H, Thierens H, Vral A, Cornelissen M, De Ridder
L: Quantification of apoptosis in lymphocyte subsets and ef-
fect of apoptosis on apparent expression of membrane anti-
gens. Cytometry 1997, 29:242-9
56. Hu L, Gudas LJ: Cyclic AMP analogs and retinoic acid influence
the  expression  of  retinoic  acid receptor  alpha,  beta, and
gamma mRNAs in F9 teratocarcinoma cells. Mol Cell Biol 1990,
10:391-6
57. Silberstein L, Webster SG, Travis M, Blau HM: Developmental pro-
gression of myosin gene expression in cultured muscle cells.
Cell 1986, 46:1075-81
58. Boylan JF, Lohnes D, Taneja R, Chambon P, Gudas LJ: Loss of retin-
oic acid receptor gamma function in F9 cells by gene disrup-
tion  results  in  aberrant  Hoxa-1  expression  and
differentiation upon retinoic acid treatment. Proc. Natl. Acad.
Sci. U.S.A 1993, 90:9601-9605
59. Taneja R, Rochette-Egly C, Plassat JL, Penna L, Gaub MP, Chambon P:
Phosphorylation of activation functions AF-1 and AF-2 of
RAR alpha and RAR gamma is indispensable for differentia-
t i o n  o f  F 9  ce l l s  u p o n  r e t i n o i c a ci d  a n d  cA M P  t r e a t m e n t .
EMBO J 1997, 16:6452-6465
60. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD: Interaction
o f  t h y r o i d - h o r m o n e  r e ce p t o r  w i t h  a  co n s e r v e d  t r a n s cr i p -
tional mediator. Nature 1995, 374:91-94
61. vom Baur E, Zechel C, Heery D, Heine MJ, Garnier JM, Vivat V, Le
Douarin B, Gronemeyer H, Chambon P, Losson R: Differential lig-
and-dependent interactions between the AF-2 activating do-
main of nuclear receptors and the putative transcriptional
intermediary factors mSUG1 and TIF1. EMBO J 1996, 15:110-
124
62. Alzuherri HM, White RJ: Regulation of a TATA-binding protein-
associated factor during cellular differentiation. J. Biol. Chem
1998, 273:17166-17171
63. Alzuherri HM, White RJ: Regulation of RNA polymerase I tran-
scription in response to F9 embryonal carcinoma stem cell
differentiation. J. Biol. Chem 1999, 274:4328-4334
64. Faria TN, Mendelsohn C, Chambon P, Gudas LJ: The targeted dis-
ruption of both alleles of RARbeta(2) in F9 cells results in the
loss of retinoic acid-associated growth arrest. J Biol Chem 1999,
274(38):26783-8
65. Lavigne AC, Gangloff YG, Carr L, Mengus G, Birck C, Poch O, Romier
C, Moras D, Davidson I: Synergistic transcriptional activation
b y  T A T A - b i n d i n g  p r o t e i n  a n d  h T A F I I 2 8  r e q u i r e s  s p e ci f i c
amino acids of the hTAFII28 histone fold. Mol. Cell Biol 1999,
19:5050-5060
66. Brou C, Wu J, Ali S, Scheer E, Lang C, Davidson I, Chambon P, Tora
L: Different TBP-associated factors are required for mediat-
ing  the  stimulation  of  transcription  in  vitro  by  the  acidic
transactivator GAL-VP16 and the two nonacidic activation
functions of the estrogen receptor. Nucleic Acids Res 1993, 21:5-
12
67. Lescure A, Lutz Y, Eberhard D, Jacq X, Krol A, Grummt I, Davidson
I, Chambon P, Tora L: The N-terminal domain of the human
T A T A - b i n d i n g  p r o t e i n  p l a y s  a  r o l e  i n  t r a n s cr i p t i o n  f r o m
TATA-containing  RNA  polymerase  II  and  III  promoters.
EMBO J 1994, 13:1166-1175
68. Jacq X, Brou C, Lutz Y, Davidson I, Chambon P, Tora L:  Human
TAFII30 is present in a distinct TFIID complex and is re-
quired for transcriptional activation by the estrogen recep-
tor. Cell 1994, 79:107-117
69. Dubrovskaya V, Lavigne AC, Davidson I, Acker J, Staub A, Tora L:
Distinct domains of hTAFII100 are required for functional
interaction with transcription factor TFIIF beta (RAP30) and
incorporation into the TFIID complex. EMBO J 1996, 15:3702-
3712
70. Lavigne AC, Mengus G, May M, Dubrovskaya V, Tora L, Chambon P,
Davidson I: Multiple interactions between hTAFII55 and other
TFIID subunits. Requirements for the formation of stable
ternary complexes between hTAFII55 and the TATA-bind-
ing protein. J. Biol. Chem 1996, 271:19774-19780